SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
 
SCHEDULE 13G
 (Rule 13d-102)
(Amendment No. 2)
 
INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
TO RULE 13d-1(b) (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO
RULE 13d-2(b)
 
 RELMADA THERAPEUTICS INC.
 (Name of Issuer)
 
COMMON STOCK, $0.001 PAR VALUE PER SHARE
(Title of Class of Securities)
 
75955J1204
(CUSIP Number)
 
Copy to:
Barry Honig
555 South Federal Highway #450
Boca Raton, FL 33432
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
 
October 31, 2016
(Date of Event Which Requires Filing of This Statement)
 
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
 
[   ] Rule 13d-1(b)
[ x] Rule 13d-1(c)
[   ] Rule 13d-1(d)
 
(Page 1 of 6 Pages)
 
 
 

 
 
 
CUSIP No. 75955J204
 
 
 
1
 
 
NAME OF REPORTING PERSONS
S.S. OR I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
 
Barry Honig
 
2
 
 
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*                                                                                                                                                      (a) ☐
                                                                                                                                                                                                                                                                       (b) ☐
 
 
3
 
 
SEC USE ONLY
 
 
4
 
 
CITIZENSHIP OR PLACE OF ORGANIZATION
 
United States
 
 
 
 
NUMBER OF SHARES
 
 
5
 
 
SOLE VOTING POWER
 
0
 
 
BENEFICIALLY
OWNED BY
 
 
6
 
 
SHARED VOTING POWER
 
0
 
 
EACH
REPORTING
 
 
7
 
 
SOLE DISPOSITIVE POWER
 
0
 
 
PERSON WITH
 
 
8
 
 
SHARED DISPOSITIVE POWER
 
0
 
 
 
9
 
 
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
 
0
 
 
10
 
 
CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
 
 
 
11
 
 
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
 
0%
 
 
12
 
 
TYPE OF REPORTING PERSON*
 
IN
 
 
 
 
 
CUSIP No. 75955J204
 
 
 
1
 
 
NAME OF REPORTING PERSONS
S.S. OR I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
 
Southern Biotech, Inc.
 
2
 
 
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*                                                                                                                                                    (a) ☐
                                                                                                                                                                                                                                                                      (b) ☐
 
 
3
 
 
SEC USE ONLY
 
 
 
4
 
 
CITIZENSHIP OR PLACE OF ORGANIZATION
 
Nevada
 
 
 
 
NUMBER OF SHARES
 
 
5
 
 
SOLE VOTING POWER
 
0
 
 
BENEFICIALLY
OWNED BY
 
 
6
 
 
SHARED VOTING POWER
 
0
 
 
EACH
REPORTING
 
 
7
 
 
SOLE DISPOSITIVE POWER
 
0
 
 
PERSON WITH
 
 
8
 
 
SHARED DISPOSITIVE POWER
 
0
 
 
 
9
 
 
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
 
0
 
 
10
 
 
CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
 
 
 
11
 
 
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
 
0 %
 
 
12
 
 
TYPE OF REPORTING PERSON*
 
OO
 
 
 
 
 
 Item 1(a)
 
 
        
Name of Issuer:
 
Relmada Therapeutics, Inc.
 
Item 1(b).            
Address of Issuer's Principal Executive Offices:
 
275 Madison Avenue, Suite 702
New York, New York 10016
 
Item 2(a).            
Name of Person Filing.
 
The statement is filed on behalf of Barry Honig and Southern Biotech, Inc. (collectively the “Reporting Persons”).
 
Item 2(b).            
Address of Principal Business Office or, if None, Residence.
 
555 South Federal Highway #450, Boca Raton, FL 33432
 
Item 2(c).             
Citizenship.
 
United States/Nevada
 
Item 2(d).             
Title of Class of Securities.
 
Common Stock, $0.001 par value per share.
 
Item 2(e).            
CUSIP Number.
 
7955J1204
 
 Item 3.  
 Type of Person
 
Not applicable.
 
Item 4.
Ownership.
 
(a) Amount beneficially owned: 0
 
(b) Percent of class: 0%
 
(c) Number of shares as to which the person has:
 
(i) Sole power to vote or to direct the vote: 0
 
(ii) Shared power to vote or to direct the vote: 0
 
(iii) Sole power to dispose or to direct the disposition of: 0
 
(iv) Shared power to dispose or to direct the disposition of: 0
 
 Item 5. 
Ownership of Five Percent or Less of a Class.
 
Not applicable.
 
 
 
 
Item 6.         
Ownership of More than Five Percent on Behalf of Another Person.
 
Not Applicable
 
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported by the Parent Holding Company.
 
Not applicable.
 
Item 8.         
Identification and Classification of Members of the Group.
 
Not applicable.
 
Item 9.         
Notice of Dissolution of Group.
 
Not applicable.
 
Item 10.        
Certifications.
 
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
 
 
 
 
SIGNATURE
 
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
 
 
 
 
 
Date: October 31, 2016
By: 
/s/ Barry Honig
 
 
 
Barry Honig
 
 
 
 
 
 
 
 
 
 
Southern Biotech, Inc.
 
 
Date: October 31, 2016
 
By: 
 
/s/ Barry Honig
 
 
 
Barry Honig, President